Shots:

• Pfenex and Alvogen announce that EMA has accepted MAA for its PF708- a biosimilar to Eli Lilly’s Forsteo which has generated $289M in EU & $1.6B globally in 2018 for the treatment of osteoporosis
• is expected to receive marketing authorization in all 28 states of EU- as well as in Iceland- Liechtenstein and Norway- following to the EMA approval
• Teriparatide (PF708) is developed by Pfenex utilizing its Pfenex Expression Technology- pursuant to the 505(b)(2) regulatory pathway in the US and will be promoted & commercialized by Theramex in Europe

Ref: GlobeNewsWire | Image: Linkedin